| Year |
Citation |
Score |
| 2000 |
Ouagazzal AM, Creese I. Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacology, Biochemistry, and Behavior. 67: 637-45. PMID 11164096 DOI: 10.1016/S0091-3057(00)00406-8 |
0.341 |
|
| 1998 |
Creese I, Tepper JM. Antisense knockdown of brain dopamine receptors. Advances in Pharmacology (San Diego, Calif.). 42: 517-20. PMID 9327954 DOI: 10.1016/S1054-3589(08)60803-0 |
0.348 |
|
| 1997 |
Dong ZJ, Chen LJ, Jin GZ, Creese I. GTP regulation of (-)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum. Biochemical Pharmacology. 54: 227-32. PMID 9271326 DOI: 10.1016/S0006-2952(97)00152-4 |
0.469 |
|
| 1997 |
Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 78: 985-96. PMID 9174067 DOI: 10.1016/S0306-4522(96)00631-8 |
0.537 |
|
| 1997 |
Tepper JM, Sun BC, Martin LP, Creese I. Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 2519-30. PMID 9065512 DOI: 10.1523/Jneurosci.17-07-02519.1997 |
0.341 |
|
| 1997 |
Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. The Journal of Pharmacology and Experimental Therapeutics. 280: 561-9. PMID 9023264 |
0.517 |
|
| 1997 |
Florijn WJ, Tarazi FI, Creese I. Chapter 4 Dopamine receptors Principles of Medical Biology. 8: 73-94. DOI: 10.1016/S1569-2582(97)80066-9 |
0.491 |
|
| 1996 |
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. The Journal of Neuropsychiatry and Clinical Neurosciences. 8: 223-6. PMID 9081563 DOI: 10.1176/JNP.8.2.223 |
0.6 |
|
| 1996 |
Tarazi FI, Florijn WJ, Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 128: 371-9. PMID 8986008 DOI: 10.1007/s002130050147 |
0.474 |
|
| 1996 |
Creese I. Antisense “knockout” of brain dopamine receptors: Potential antipsychotics? European Neuropsychopharmacology. 6: S4-27. DOI: 10.1016/0924-977X(96)82890-2 |
0.436 |
|
| 1995 |
Pothos EN, Creese I, Hoebel BG. Restricted eating with weight loss selectively decreases extracellular dopamine in the nucleus accumbens and alters dopamine response to amphetamine, morphine, and food intake. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 15: 6640-50. PMID 7472425 DOI: 10.1523/Jneurosci.15-10-06640.1995 |
0.347 |
|
| 1994 |
Koutouzis TK, Borlongan CV, Scorcia T, Creese I, Cahill DW, Freeman TB, Sanberg PR. Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Research. 646: 242-6. PMID 8069670 DOI: 10.1016/0006-8993(94)90085-X |
0.343 |
|
| 1994 |
Zang Z, Florijn W, Creese I. Reduction in muscarinic receptors by antisense oligodeoxynucleotide. Biochemical Pharmacology. 48: 225-8. PMID 8053918 DOI: 10.1016/0006-2952(94)90090-6 |
0.338 |
|
| 1993 |
Zhang M, Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neuroscience Letters. 161: 223-6. PMID 7903803 DOI: 10.1016/0304-3940(93)90299-Z |
0.436 |
|
| 1993 |
Zang Z, Buzsaki G, Creese I. Denervation-induced changes in hippocampal muscarinic receptor subtypes and their mRNAs Life Sciences. 52: 592. DOI: 10.1016/0024-3205(93)90401-N |
0.398 |
|
| 1992 |
Xu SX, Monsma FJ, Sibley DR, Creese I. Regulation of D1A and D2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sciences. 50: 383-96. PMID 1732708 DOI: 10.1016/0024-3205(92)90440-Z |
0.628 |
|
| 1992 |
Creese I, Sibley DR, Xu SX. Expression of rat striatal D1 and D2 dopamine receptor mRNAs: ontogenetic and pharmacological studies. Neurochemistry International. 20: 45S-48S. PMID 1365454 DOI: 10.1016/0197-0186(92)90209-A |
0.547 |
|
| 1992 |
Kirch DG, Taylor TR, Creese I, Xu SX, Wyatt RJ. Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors. The Journal of Pharmacy and Pharmacology. 44: 89-92. PMID 1352822 DOI: 10.1111/J.2042-7158.1992.Tb03567.X |
0.453 |
|
| 1991 |
Tepper JM, Creese I, Schwartz DH. Stimulus-evoked changes in neostriatal dopamine levels in awake and anesthetized rats as measured by microdialysis. Brain Research. 559: 283-92. PMID 1794102 DOI: 10.1016/0006-8993(91)90013-L |
0.302 |
|
| 1991 |
Xu SX, Hatada Y, Black LE, Creese I, Sibley DR. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. The Journal of Pharmacology and Experimental Therapeutics. 257: 608-15. PMID 1674530 |
0.639 |
|
| 1991 |
Creese I, Xu SX. Regulation of dopamine D2 receptors: molecular mechanisms European Neuropsychopharmacology. 1: 408-409. |
0.409 |
|
| 1990 |
van Tol HH, Riva M, Civelli O, Creese I. Lack of effect of chronic dopamine receptor blockade on D2 dopamine receptor mRNA level. Neuroscience Letters. 111: 303-8. PMID 1970862 DOI: 10.1016/0014-2999(90)94533-4 |
0.479 |
|
| 1990 |
Creese I, Van Tol HHM, Riva M, Civelli O. Lack of effect of chromic dopamine receptor blockade on D2 dopamine receptor mRNA levels European Journal of Pharmacology. 183: 1404. |
0.475 |
|
| 1989 |
Norman AB, Eubanks JH, Creese I. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain. The Journal of Pharmacology and Experimental Therapeutics. 248: 1116-22. PMID 2703964 |
0.377 |
|
| 1989 |
Riva MA, Creese I. Reevaluation of the regulation of beta-adrenergic receptor binding by desipramine treatment. Molecular Pharmacology. 36: 211-8. PMID 2546051 |
0.379 |
|
| 1989 |
Riva MA, Creese I. Comparison of two putatively selective radioligands for labeling central nervous system beta-adrenergic receptors: inadequacy of [3H]dihydroalprenolol. Molecular Pharmacology. 36: 201-10. PMID 2546050 |
0.472 |
|
| 1988 |
Hess EJ, Norman AB, Creese I. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 8: 2361-70. PMID 2907912 |
0.421 |
|
| 1988 |
Friedhoff AJ, Pickar D, Axelrod J, Creese I, Davis KL, Gallagher DW, Greengard P, Housman D, Maas JW, Richelson E. Neurochemistry and neuropharmacology. Schizophrenia Bulletin. 14: 399-412. PMID 2905525 DOI: 10.1093/Schbul/14.3.399 |
0.343 |
|
| 1988 |
Battaglia G, Norman AB, Creese I. Age-related differential recovery rates of rat striatal D-1 dopamine receptors following irreversible inactivation. European Journal of Pharmacology. 145: 281-90. PMID 2895004 DOI: 10.1016/0014-2999(88)90431-1 |
0.476 |
|
| 1987 |
Hess EJ, Battaglia G, Norman AB, Creese I. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro. Molecular Pharmacology. 31: 50-7. PMID 3100940 |
0.493 |
|
| 1987 |
Koob GF, Le HT, Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neuroscience Letters. 79: 315-20. PMID 2958724 DOI: 10.1016/0304-3940(87)90451-4 |
0.385 |
|
| 1987 |
Norman AB, Battaglia G, Creese I. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 7: 1484-91. PMID 2952771 |
0.485 |
|
| 1987 |
Hess EJ, Bracha HS, Kleinman JE, Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sciences. 40: 1487-97. PMID 2951573 DOI: 10.1016/0024-3205(87)90381-X |
0.45 |
|
| 1987 |
Battaglia G, Norman AB, Creese I. Differential serotonin2 receptor recovery in mature and senescent rat brain after irreversible receptor modification: effect of chronic reserpine treatment. The Journal of Pharmacology and Experimental Therapeutics. 243: 69-75. PMID 2889827 |
0.396 |
|
| 1986 |
Norman AB, Battaglia G, Creese I. Regulation of putative muscarinic cholinergic receptor subtypes in rat brain. Neurochemistry International. 9: 337-47. PMID 20493134 DOI: 10.1016/0197-0186(86)90071-9 |
0.464 |
|
| 1986 |
Morrow AL, Chen AD, Creese I. Modulation of alpha-1 adrenergic receptors in rat brain following chronic reserpine. Neurochemistry International. 8: 243-7. PMID 20493053 DOI: 10.1016/0197-0186(86)90170-1 |
0.609 |
|
| 1986 |
Norman AB, Blaker SN, Thal L, Creese I. Effects of aging and cholinergic deafferentation on putative muscarinic cholinergic receptor subtypes in rat cerebral cortex. Neuroscience Letters. 70: 289-94. PMID 3774231 DOI: 10.1016/0304-3940(86)90479-9 |
0.415 |
|
| 1986 |
Norman AB, Creese I. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain. Molecular Pharmacology. 30: 96-103. PMID 3755499 |
0.447 |
|
| 1986 |
Hess EJ, Albers LJ, Le H, Creese I. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. The Journal of Pharmacology and Experimental Therapeutics. 238: 846-54. PMID 3018223 |
0.469 |
|
| 1986 |
Morrow AL, Creese I. Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding. Molecular Pharmacology. 29: 321-30. PMID 3010073 |
0.562 |
|
| 1986 |
Battaglia G, Norman AB, Hess EJ, Creese I. Forskolin potentiates the stimulation of rat striatal adenylate cyclase mediated by D-1 dopamine receptors, guanine nucleotides, and sodium fluoride. Journal of Neurochemistry. 46: 1180-5. PMID 3005508 DOI: 10.1111/j.1471-4159.1986.tb00635.x |
0.343 |
|
| 1986 |
Amalric M, Koob GF, Creese I, Swerdlow NR. "Selective" D-1 and D-2 receptor antagonists fail to differentially alter supersensitive locomotor behavior in the rat. Life Sciences. 39: 1985-93. PMID 2946915 DOI: 10.1016/0024-3205(86)90322-X |
0.429 |
|
| 1986 |
Battaglia G, Norman AB, Hess EJ, Creese I. Functional recovery of D1 dopamine receptor-mediated stimulation of rat striatal adenylate cyclase activity following irreversible receptor modification by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): evidence for spare receptors. Neuroscience Letters. 69: 290-5. PMID 2945128 |
0.442 |
|
| 1986 |
Battaglia G, Norman AB, Newton PL, Creese I. In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline: a technique for investigating S2 serotonin receptor recovery. Journal of Neurochemistry. 46: 589-93. PMID 2934516 DOI: 10.1111/j.1471-4159.1986.tb13008.x |
0.451 |
|
| 1986 |
Creese I, Hess EJ. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia. Clinical Neuropharmacology. 9: 14-6. PMID 2882838 |
0.348 |
|
| 1986 |
Hess EJ, Creese I. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390. Psychopharmacology Bulletin. 22: 605-12. PMID 2879304 |
0.413 |
|
| 1986 |
Hess EJ, Creese I. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390. Advances in Experimental Medicine and Biology. 204: 29-52. PMID 2878579 |
0.413 |
|
| 1986 |
Hess EJ, Battaglia G, Norman AB, Iorio LC, Creese I. Guanine nucleotide regulation of agonist interactions at [3H]SCH23390-labeled D1 dopamine receptors in rat striatum. European Journal of Pharmacology. 121: 31-8. PMID 2869957 DOI: 10.1016/0014-2999(86)90389-4 |
0.572 |
|
| 1985 |
Morrow AL, Norman AB, Battaglia G, Loy R, Creese I. Up-regulation of serotonergic binding sites labeled by [3H]WB4101 following fimbrial transection and 5,7-dihydroxytryptamine-induced lesions. Life Sciences. 37: 1913-22. PMID 4058260 DOI: 10.1016/0024-3205(85)90009-8 |
0.603 |
|
| 1985 |
Morrow AL, Loy R, Creese I. Alteration of nicotinic cholinergic agonist binding sites in hippocampus after fimbria transection. Brain Research. 334: 309-14. PMID 3995322 DOI: 10.1016/0006-8993(85)90223-9 |
0.576 |
|
| 1985 |
Leff SE, Creese I. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor. Molecular Pharmacology. 27: 184-92. PMID 3969067 |
0.542 |
|
| 1985 |
Leff SE, Hamblin MW, Creese I. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states. Molecular Pharmacology. 27: 171-83. PMID 3969066 |
0.567 |
|
| 1985 |
Morrow AL, Battaglia G, Norman AB, Creese I. Identification of subtypes of [3H]prazosin-labelled alpha 1 receptor binding sites in rat brain. European Journal of Pharmacology. 109: 285-7. PMID 2987000 DOI: 10.1016/0014-2999(85)90432-7 |
0.593 |
|
| 1985 |
Battaglia G, Norman AB, Hess EJ, Creese I. D2 dopamine receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in rat striatum. Neuroscience Letters. 59: 177-82. PMID 2932659 DOI: 10.1016/0304-3940(85)90196-X |
0.351 |
|
| 1985 |
Norman AB, Battaglia G, Creese I. [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity. Molecular Pharmacology. 28: 487-94. PMID 2867462 |
0.417 |
|
| 1985 |
Creese I, Chen A. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. European Journal of Pharmacology. 109: 127-8. PMID 2859993 DOI: 10.1016/0014-2999(85)90549-7 |
0.498 |
|
| 1984 |
Leff SE, Chen A, Creese I. Sulpiride isomers exhibit reversed stereospecificity for D-1 and D-2 dopamine receptors in the CNS. Neuropharmacology. 23: 589-90. PMID 6738827 DOI: 10.1016/0028-3908(84)90034-0 |
0.45 |
|
| 1984 |
Hamblin MW, Leff SE, Creese I. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochemical Pharmacology. 33: 877-87. PMID 6712712 DOI: 10.1016/0006-2952(84)90441-6 |
0.535 |
|
| 1984 |
Leff SE, Gariano R, Creese I. Dopamine receptor turnover rates in rat striatum are age-dependent. Proceedings of the National Academy of Sciences of the United States of America. 81: 3910-4. PMID 6587399 |
0.52 |
|
| 1984 |
Creese I, Sibley DR, Leff SE. Agonist interactions with dopamine receptors: focus on radioligand-binding studies. Federation Proceedings. 43: 2779-84. PMID 6383871 |
0.681 |
|
| 1984 |
Norman AB, Battaglia G, Morrow AL, Creese I. [3H]WB4101 labels S1 serotonin receptors in rat cerebral cortex. European Journal of Pharmacology. 106: 461-2. PMID 6152223 DOI: 10.1016/0014-2999(84)90743-X |
0.529 |
|
| 1983 |
Loy R, Morrow AL, Creese I. Cholinergic denervation induces adrenergic receptor increases: correlation with sympathetic axon sprouting in hippocampus. Birth Defects Original Article Series. 19: 409-15. PMID 6871408 |
0.486 |
|
| 1983 |
Sibley DR, Mahan LC, Creese I. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Molecular Pharmacology. 23: 295-302. PMID 6835198 |
0.697 |
|
| 1983 |
Sibley DR, Creese I. Regulation of ligand binding to pituitary D-2 dopaminergic receptors. Effects of divalent cations and functional group modification. The Journal of Biological Chemistry. 258: 4957-65. PMID 6833284 |
0.657 |
|
| 1983 |
Leff SE, Creese I. Dopaminergic D-3 binding sites are not presynaptic autoreceptors. Nature. 306: 586-9. PMID 6417548 |
0.501 |
|
| 1983 |
Creese I, Sibley DR, Leff S. Classification of dopamine receptors. Advances in Biochemical Psychopharmacology. 37: 255-66. PMID 6416028 |
0.654 |
|
| 1983 |
Creese I, Sibley DR, Hamblin MW, Leff SE. Dopamine receptors in the central nervous system. Advances in Biochemical Psychopharmacology. 36: 125-34. PMID 6344562 DOI: 10.1016/B978-008055232-3.60151-5 |
0.659 |
|
| 1983 |
Morrow AL, Loy R, Creese I. Septal deafferentation increases hippocampal adrenergic receptors: correlation with sympathetic axon sprouting. Proceedings of the National Academy of Sciences of the United States of America. 80: 6718-22. PMID 6314338 |
0.614 |
|
| 1983 |
Sibley DR, Creese I. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Molecular Pharmacology. 23: 585-93. PMID 6223205 |
0.705 |
|
| 1983 |
Creese I, Sibley DR, Hamblin MW, Leff SE. The classification of dopamine receptors: relationship to radioligand binding. Annual Review of Neuroscience. 6: 43-71. PMID 6220666 DOI: 10.1146/Annurev.Ne.06.030183.000355 |
0.694 |
|
| 1983 |
Hamblin MW, Creese I. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sciences. 32: 2247-55. PMID 6133202 DOI: 10.1016/0024-3205(83)90423-X |
0.543 |
|
| 1983 |
Creese I. Dopamine receptors explained | DIE DOPAMIN-REZEPTOREN Nervenheilkunde. 2: 88-93. DOI: 10.1016/0166-2236(82)90019-4 |
0.455 |
|
| 1983 |
Leff SE, Creese I. Dopamine receptors re-explained Trends in Pharmacological Sciences. 4: 463-467. DOI: 10.1016/0165-6147(83)90494-7 |
0.496 |
|
| 1983 |
Creese I, Morrow AL, Hamblin MW, Leff SE, Sibley DR. Radioligand binding studies of dopamine receptors in the central nervous system Advances in the Biosciences. 44: 1-50. |
0.71 |
|
| 1982 |
Leff SE, Creese I. Solubilization of D-2 dopamine receptors from canine caudate: agonist-occupation stabilizes guanine nucleotide sensitive receptor complexes. Biochemical and Biophysical Research Communications. 108: 1150-7. PMID 7181887 DOI: 10.1016/0006-291X(82)92121-0 |
0.461 |
|
| 1982 |
Hamblin MW, Creese I. Heat treatment mimics guanosine-5'-triphosphate effects on dopaminergic 3H-ligand binding to bovine caudate membranes. Molecular Pharmacology. 21: 52-6. PMID 7132962 |
0.435 |
|
| 1982 |
Creese I, Leff SE. Dopamine receptors: a classification. Journal of Clinical Psychopharmacology. 2: 329-35. PMID 7130434 DOI: 10.1097/00004714-198210000-00009 |
0.56 |
|
| 1982 |
Mackay AV, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Synder SH. Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry. 39: 991-7. PMID 7115016 DOI: 10.1001/Archpsyc.1982.04290090001001 |
0.459 |
|
| 1982 |
Hamblin MW, Creese I. 3H-dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine nucleotides and sodium. Life Sciences. 30: 1587-95. PMID 7078356 DOI: 10.1016/0024-3205(82)90248-X |
0.512 |
|
| 1982 |
Sibley DR, Weinberger S, Segal DS, Creese I. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding. Experientia. 38: 1224-5. PMID 6890464 DOI: 10.1007/BF01959753 |
0.703 |
|
| 1982 |
Creese I, Morrow AL, Leff SE, Sibley DR, Hamblin MW. Dopamine receptors in the central nervous system. International Review of Neurobiology. 23: 255-301. PMID 6749737 |
0.725 |
|
| 1982 |
Creese I, Kuczenski R, Segal D. Lack of behavioral evidence for dopamine autoreceptor subsensitivity after acute electroconvulsive shock. Pharmacology, Biochemistry, and Behavior. 17: 375-6. PMID 6291070 DOI: 10.1016/0091-3057(82)90096-X |
0.307 |
|
| 1982 |
Sibley DR, De Lean A, Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. The Journal of Biological Chemistry. 257: 6351-61. PMID 6176582 |
0.697 |
|
| 1982 |
Hamblin MW, Creese I. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes. Molecular Pharmacology. 21: 44-51. PMID 6127621 |
0.509 |
|
| 1982 |
Sibley DR, Leff SE, Creese I. Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sciences. 31: 637-45. PMID 6127585 DOI: 10.1016/0024-3205(82)90764-0 |
0.682 |
|
| 1982 |
Creese I, Sibley DR. Comments on the commentary by Dr. Seeman Biochemical Pharmacology. 31: 2568-2569. DOI: 10.1016/0006-2952(82)90701-8 |
0.444 |
|
| 1982 |
Leff SE, Creese I. Solubilization of a guanine nucleotide sensitive form of the D-2 dopamine receptor from brain requires agonist occupancy Federation Proceedings. 41: No. 7968. |
0.435 |
|
| 1981 |
Leff S, Sibley DR, Hamblin M, Creese I. Ascorbic acid enables reversible dopamine receptor 3H-agonist binding. Life Sciences. 29: 2081-90. PMID 7311734 DOI: 10.1016/0024-3205(81)90665-2 |
0.705 |
|
| 1981 |
Leff S, Adams L, Hyttel J, Creese I. Kainate lesion dissociates striatal dopamine receptor radioligand binding sites. European Journal of Pharmacology. 70: 71-5. PMID 7215442 DOI: 10.1016/0014-2999(81)90434-9 |
0.604 |
|
| 1981 |
Creese I, Sibley DR, Leff S, Hamblin M. Dopamine receptors: subtypes, localization and regulation. Federation Proceedings. 40: 147-52. PMID 7007083 |
0.677 |
|
| 1981 |
Meltzer HY, Busch DA, Creese IR, Snyder SH, Fang VS. Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls. Psychiatry Research. 5: 95-105. PMID 6944710 DOI: 10.1016/0165-1781(81)90065-2 |
0.322 |
|
| 1981 |
Creese I, Sibley DR. Receptor adaptations to centrally acting drugs. Annual Review of Pharmacology and Toxicology. 21: 357-91. PMID 6263174 DOI: 10.1146/annurev.pa.21.040181.002041 |
0.62 |
|
| 1981 |
Sanberg PR, Creese I. Dopamine receptor stimulation and striatal kainic acid neurotoxicity. The Journal of Pharmacy and Pharmacology. 33: 674-5. PMID 6117626 DOI: 10.1111/J.2042-7158.1981.Tb13900.X |
0.42 |
|
| 1981 |
Tune LE, Creese I, DePaulo JR, Slavney PR, Snyder SH. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients. The Journal of Nervous and Mental Disease. 169: 60-3. PMID 6108981 DOI: 10.1097/00005053-198101000-00009 |
0.518 |
|
| 1981 |
Hamblin M, Creese I. Receptor binding and the discovery of psychotherapeutic drugs Drug Development Research. 1: 343-372. |
0.415 |
|
| 1980 |
Sibley DR, Creese I. Dopamine receptor binding in bovine intermediate lobe pituitary membranes. Endocrinology. 107: 1405-9. PMID 7428676 DOI: 10.1210/endo-107-5-1405 |
0.65 |
|
| 1980 |
Sibley DR, Creese I. Pseudo non-competitive agonist interactions with dopamine receptors. European Journal of Pharmacology. 65: 131-3. PMID 7398773 |
0.654 |
|
| 1980 |
Hamblin M, Creese I. Phenoxybenzamine discriminates multiple dopamine receptors. European Journal of Pharmacology. 65: 119-21. PMID 7398772 |
0.486 |
|
| 1980 |
Usdin TB, Creese I, Snyder SH. Regulation by cations of [3H]spiroperidol binding associated with dopamine receptors of rat brain. Journal of Neurochemistry. 34: 669-76. PMID 6766497 DOI: 10.1111/j.1471-4159.1980.tb11196.x |
0.667 |
|
| 1980 |
Mackay AV, Bird ED, Spokes EG, Rossor M, Iversen LL, Creese I, Snyder SH. Dopamine receptors and schizophrenia: drug effect or illness? Lancet. 2: 915-6. PMID 6107564 DOI: 10.1016/S0140-6736(80)92072-3 |
0.492 |
|
| 1980 |
Creese I, Snyder SH. Chronic neuroleptic treatment and dopamine receptor regulation. Advances in Biochemical Psychopharmacology. 24: 89-94. PMID 6105809 |
0.418 |
|
| 1980 |
Creese I. Central nervous system dopamine receptors. Advances in Biochemical Psychopharmacology. 21: 235-42. PMID 6103649 |
0.486 |
|
| 1980 |
Tune LE, Creese I, Coyle JT, Pearlson G, Snyder SH. Low neuroleptic serum levels in patients receiving fluphenazine decanoate. The American Journal of Psychiatry. 137: 80-2. PMID 6101523 DOI: 10.1176/ajp.137.1.80 |
0.418 |
|
| 1979 |
Creese I, Sibley DR. Radioligand binding studies: evidence for multiple dopamine receptors. Communications in Psychopharmacology. 3: 385-95. PMID 546587 |
0.71 |
|
| 1979 |
Creese I, Stewart K, Snyder SH. Species variation in dopamine receptor binding. European Journal of Pharmacology. 60: 55-66. PMID 520417 DOI: 10.1016/0014-2999(79)90052-9 |
0.662 |
|
| 1979 |
Creese I, Usdin TB, Snyder SH. Dopamine receptor binding regulated by guanine nucleotides. Molecular Pharmacology. 16: 69-76. PMID 481426 |
0.551 |
|
| 1979 |
Creese I, Padgett L, Fazzini E, Lopez F. 3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors. European Journal of Pharmacology. 56: 411-2. PMID 477735 DOI: 10.1016/0014-2999(79)90274-7 |
0.512 |
|
| 1979 |
Sibley DR, Creese I. Guanine nucleotides regulate anterior pituitary dopamine receptors. European Journal of Pharmacology. 55: 341-3. PMID 456433 DOI: 10.1016/0014-2999(79)90207-3 |
0.648 |
|
| 1979 |
Creese I, Usdin T, Snyder SH. Guanine nucleotides distinguish between two dopamine receptors. Nature. 278: 577-8. PMID 431724 DOI: 10.1038/278577a0 |
0.667 |
|
| 1979 |
Childers SR, Creese I, Snowman AM, Synder SH. Opiate receptor binding affected differentially by opiates and opioid peptides. European Journal of Pharmacology. 55: 11-8. PMID 220062 DOI: 10.1016/0014-2999(79)90142-0 |
0.5 |
|
| 1979 |
Calil HM, Avery DH, Hollister LE, Creese I, Snyder SH. Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations. Psychiatry Research. 1: 39-44. PMID 45128 DOI: 10.1016/0165-1781(79)90026-X |
0.43 |
|
| 1979 |
Freedberg KA, Innis RB, Creese I, Snyder SH. Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sciences. 24: 2467-73. PMID 39211 DOI: 10.1016/0024-3205(79)90457-0 |
0.533 |
|
| 1979 |
Creese I, Snyder SH. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding. European Journal of Pharmacology. 56: 277-81. PMID 38973 DOI: 10.1016/0014-2999(79)90184-5 |
0.515 |
|
| 1978 |
Creese I, Snyder SH. Dopamine receptor binding of 3H-ADTN (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene) regulated by guanyl nucleotides. European Journal of Pharmacology. 50: 459-61. PMID 699970 DOI: 10.1016/0014-2999(78)90156-5 |
0.688 |
|
| 1978 |
Creese I, Prosser T, Synder SH. Dopamine receptor binding: specificity, localization and regulation by ions and guanyl nucleotides. Life Sciences. 23: 495-9. PMID 692273 DOI: 10.1016/0024-3205(78)90160-1 |
0.638 |
|
| 1978 |
Thal L, Creese I, Snyder SH. 3H-Apomorphine interactions with dopamine receptors in calf brain. European Journal of Pharmacology. 49: 295-9. PMID 658143 DOI: 10.1016/0014-2999(78)90105-X |
0.684 |
|
| 1978 |
Creese I, Snyder SH. 3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. European Journal of Pharmacology. 49: 201-2. PMID 658137 DOI: 10.1016/0014-2999(78)90080-8 |
0.519 |
|
| 1978 |
Creese I, Manian AA, Prosser TD, Snyder SH. 3H-Haloperidol binding to dopamine receptors in rat corpus striatum: influence of chlorpromazine metabolites and derivatives. European Journal of Pharmacology. 47: 291-6. PMID 631182 DOI: 10.1016/0014-2999(78)90236-4 |
0.652 |
|
| 1978 |
Schwarcz R, Creese I, Coyle JT, Snyder SH. Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature. 271: 766-8. PMID 625348 DOI: 10.1038/271766a0 |
0.597 |
|
| 1977 |
Creese I, Snyder SH. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature. 270: 180-2. PMID 927531 DOI: 10.1038/270180a0 |
0.465 |
|
| 1977 |
Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science (New York, N.Y.). 197: 596-8. PMID 877576 DOI: 10.1126/science.877576 |
0.623 |
|
| 1977 |
Pardo JV, Creese I, Burt DR, Snyder SH. Ontogenesis of dopamine receptor binding in the corpus striatum of the rat. Brain Research. 125: 376-82. PMID 851885 DOI: 10.1016/0006-8993(77)90633-3 |
0.756 |
|
| 1977 |
Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science (New York, N.Y.). 196: 326-8. PMID 847477 DOI: 10.1126/science.847477 |
0.632 |
|
| 1977 |
Creese I, Schneider R, Snyder SH. 3H-Spiroperidol labels dopamine receptors in pituitary and brain. European Journal of Pharmacology. 46: 377-81. PMID 590345 DOI: 10.1016/0014-2999(77)90232-1 |
0.663 |
|
| 1977 |
Enna SJ, Bennett JP, Bylund DB, Creese I, Burt DR, Charness ME, Yamamura HI, Simantov R, Snyder SH. Neurotransmitter receptor binding: regional distribution in human brain. Journal of Neurochemistry. 28: 233-6. PMID 13155 DOI: 10.1111/j.1471-4159.1977.tb07733.x |
0.667 |
|
| 1977 |
Enna SJ, Bennett JP, Burt DR, Creese I, U'Prichard DC, Greenberg DA, Snyder SH. Stereospecificity and clinical potency of neuroleptics (reply) Nature. 267: 184. DOI: 10.1038/267184A0 |
0.526 |
|
| 1977 |
Creese I, Snyder SH. Chapter 25. Brain Neurotransmitter Receptor Binding and Neuroleptic Drugs Annual Reports in Medicinal Chemistry. 12: 249-259. DOI: 10.1016/S0065-7743(08)60310-3 |
0.393 |
|
| 1976 |
Creese I, Burt DR, Snyder SH. Dopamine receptors and average clinical doses. Science (New York, N.Y.). 194: 546. PMID 17783671 DOI: 10.1126/science.194.4264.546 |
0.539 |
|
| 1976 |
Creese I, Feinberg AP, Snyder SH. Butyrophenone influences on the opiate receptor. European Journal of Pharmacology. 36: 231-5. PMID 1261596 DOI: 10.1016/0014-2999(76)90277-6 |
0.53 |
|
| 1976 |
Burt DR, Creese I, Snyder SH. Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Molecular Pharmacology. 12: 800-12. PMID 995128 |
0.495 |
|
| 1976 |
Burt DR, Creese I, Snyder SH. Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Molecular Pharmacology. 12: 631-8. PMID 958211 |
0.446 |
|
| 1976 |
Feinberg AP, Creese I, Snyder SH. The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists. Proceedings of the National Academy of Sciences of the United States of America. 73: 4215-9. PMID 186791 DOI: 10.1073/pnas.73.11.4215 |
0.522 |
|
| 1976 |
Enna SJ, Bennett JP, Burt DR, Creese I, Snyder SH. Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature. 263: 338-41. PMID 8733 DOI: 10.1038/263338A0 |
0.542 |
|
| 1976 |
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (New York, N.Y.). 192: 481-3. PMID 3854 DOI: 10.1126/science.3854 |
0.6 |
|
| 1976 |
Burt DR, Creese I, Snyder SH. Dopamine receptor binding of multiple ligands Trans.Amer.Soc.Neurochem.. 7: no. 228. |
0.528 |
|
| 1975 |
Snyder SH, Creese I, Burt DR. The brain's dopamine receptor: labeling with (3H) dopamine and (3H) haloperidol. Psychopharmacology Communications. 1: 663-73. PMID 1241457 |
0.458 |
|
| 1975 |
Creese I, Burt DR, Synder SH. The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states. Life Sciences. 17: 1715-9. PMID 1207384 DOI: 10.1016/0024-3205(75)90118-6 |
0.642 |
|
| 1975 |
Creese I, Burt DR, Snyder SH. Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. Life Sciences. 17: 933-1001. PMID 1195989 DOI: 10.1016/0024-3205(75)90454-3 |
0.666 |
|
| 1975 |
Creese I, Pasternak GW, Pert CB, Snyder SH. Discrimination by temperature of opiate agonist and antagonist receptor binding. Life Sciences. 16: 1837-42. PMID 1152613 DOI: 10.1016/0024-3205(75)90287-8 |
0.773 |
|
| 1975 |
Burt DR, Enna SJ, Creese I, Snyder SH. Dopamine receptor binding in the corpus striatum of mammalian brain. Proceedings of the National Academy of Sciences of the United States of America. 72: 4655-9. PMID 1060143 DOI: 10.1073/pnas.72.11.4655 |
0.714 |
|
| 1975 |
Creese I, Snyder SH. Receptor binding and pharmacological activity of opiates in the guinea-pig intestine. The Journal of Pharmacology and Experimental Therapeutics. 194: 205-19. PMID 239219 |
0.477 |
|
| 1974 |
Creese I. Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. European Journal of Pharmacology. 28: 55-8. PMID 4473347 DOI: 10.1016/0014-2999(74)90111-3 |
0.379 |
|
| 1972 |
Creese I, Iversen SD. Amphetamine response in rat after dopamine neurone destruction. Nature: New Biology. 238: 247-8. PMID 4404010 DOI: 10.1038/Newbio238247A0 |
0.4 |
|
| Show low-probability matches. |